Literature DB >> 24411590

Impact of chronicity of injury on the proportion of mesenchymal stromal cells derived from anterior cruciate ligaments.

Dae-Hee Lee1, Joanne Ng2, Jong-Won Chung3, Chung Hee Sonn2, Kyung-Mi Lee4, Seung-Beom Han5.   

Abstract

BACKGROUND AIMS: The graft-healing potential of mesenchymal stromal cells (MSCs) derived from the remnants of ruptured anterior cruciate ligaments (ACLs) after ACL reconstruction may depend on the chronicity of the injury. The aim of this study was to assess the quantitative and phenotypic differences between MSCs isolated from ACL remnants in patients with (sub)acute and chronic tearing.
METHODS: Torn ACL remnants were harvested during ACL reconstruction from 41 patients, 24 with (sub)acute ACL (<6 months from injury to surgery) and 17 with chronic ACL (time interval >6 months) tears. MSCs isolated from these samples were assessed for quantitative and phenotypic differences, and the correlation between the proportion of MSCs and the chronicity of ACL tear was evaluated.
RESULTS: At passage 0, the mean proportion of MSCs (CD34(-), CD44(+), CD90(+) and CD105(+)) was higher in (sub)acute than in chronic ACL tear samples (20.69% ± 7.82% versus 9.85% ± 8.01%, P < 0.001). At passages 1 and 2, however, MSC proportions did not differ significantly in the two groups. Time interval showed a negative correlation with MSC proportion only at passage 0 (r = -0.505, P < 0.001). The optimal cutoff value for time from injury to surgery yielding <10% freshly isolated ACL-MSCs, a percentage expected to have low tissue healing potential, was 23.5 months.
CONCLUSIONS: The proportion of freshly isolated MSCs was higher in samples from patients with (sub)acute tearing than in chronic ACL tearing and negatively correlated with the time interval between trauma and surgery.
Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute ACL; anterior cruciate ligament; chronic ACL; mesenchymal stromal cells

Mesh:

Year:  2014        PMID: 24411590     DOI: 10.1016/j.jcyt.2013.08.001

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

1.  Updates in biological therapies for knee injuries: anterior cruciate ligament.

Authors:  Carlos Eduardo da Silveira Franciozi; Sheila Jean McNeill Ingham; Guilherme Conforto Gracitelli; Marcus Vinicius Malheiros Luzo; Freddie H Fu; Rene Jorge Abdalla
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

2.  Therapeutic potential of vascular stem cells for anterior cruciate ligament reconstruction.

Authors:  Tomoyuki Matsumoto; Koji Takayama; Shinya Hayashi; Takahiro Niikura; Takehiko Matsushita; Ryosuke Kuroda
Journal:  Ann Transl Med       Date:  2019-12

3.  Anterior cruciate ligament remnant tissue harvested within 3-months after injury predicts higher healing potential.

Authors:  Shurong Zhang; Tomoyuki Matsumoto; Atsuo Uefuji; Takehiko Matsushita; Koji Takayama; Daisuke Araki; Naoki Nakano; Kanto Nagai; Tokio Matsuzaki; Ryosuke Kuroda; Masahiro Kurosaka
Journal:  BMC Musculoskelet Disord       Date:  2015-12-18       Impact factor: 2.362

4.  Anterior cruciate ligament - updating article.

Authors:  Marcus Vinicius Malheiros Luzo; Carlos Eduardo da Silveira Franciozi; Fernando Cury Rezende; Guilherme Conforto Gracitelli; Pedro Debieux; Moisés Cohen
Journal:  Rev Bras Ortop       Date:  2016-06-06

Review 5.  Is Remnant Preservation in Anterior Cruciate Ligament Reconstruction Superior to the Standard Technique? A Systematic Review and Meta-Analysis.

Authors:  Han Wang; Ziming Liu; Yuwan Li; Yihang Peng; Wei Xu; Ning Hu; Wei Huang
Journal:  Biomed Res Int       Date:  2019-12-11       Impact factor: 3.411

6.  Impact of Surgical Timing on Clinical Outcomes in Anatomic Double-Bundle Anterior Cruciate Ligament Reconstruction Using Hamstring Tendon Autografts.

Authors:  Rikiya Baba; Eiji Kondo; Koji Iwasaki; Zenta Joutoku; Jun Onodera; Tomohiro Onodera; Tomonori Yagi; Norimasa Iwasaki; Kazunori Yasuda
Journal:  Orthop J Sports Med       Date:  2019-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.